Mupirocin Shortage: What Providers and Prescribers Need to Know in 2026

For clinicians who routinely prescribe mupirocin for impetigo, secondary skin infections, and off-label MRSA decolonization, understanding the current supply landscape is important for managing patient expectations and having alternatives ready. Here is a comprehensive 2026 update for prescribers.

Current Supply Status

As of 2026, the FDA Drug Shortage Database does not list mupirocin as a current shortage drug. Multiple generic manufacturers continue to supply the U.S. market with mupirocin 2% ointment and 2% cream. The global mupirocin market — estimated at approximately $400 million in 2022 — is driven by North American demand (roughly 55% of global market), and commercial production remains active.

Clinically relevant supply considerations in 2026:

All brand-name versions discontinued: Bactroban ointment, Bactroban nasal ointment (FDA approval withdrawn September 2025 — not for safety reasons), and Centany are no longer manufactured. Prescriptions are filled with generic mupirocin.

Cream formulation less available: The 2% cream is less commonly stocked than the ointment and may be unavailable at smaller pharmacies.

Seasonal demand: Local pharmacy stock-outs are most common in late summer and early fall when impetigo is most prevalent.

Resistance Considerations in 2026

Mupirocin resistance is an increasingly important clinical concern that affects prescribing strategy more than supply availability. Two resistance phenotypes are clinically recognized:

Low-level resistance (MuL): MIC 8–256 mg/L, typically due to point mutations in the isoleucyl-tRNA synthetase gene (ileS). Mupirocin may still achieve clinical effect depending on formulation and application site.

High-level resistance (MuH): MIC >256 mg/L, mediated by the MupA gene (a separate, acquired isoleucyl-tRNA synthetase). Mupirocin is clinically ineffective against MuH strains. Nares decolonization success rates fall below 30%. A second high-level resistant synthetase (MupB) was identified in 2012.

The MupA gene may co-transfer with resistance genes for triclosan, tetracycline, and trimethoprim, further complicating treatment of resistant strains. Clinicians treating MRSA decolonization failures should consider culture-based susceptibility testing.

FDA-Approved Indications and Key Off-Label Uses

Approved (ointment): Impetigo due to susceptible S. aureus and S. pyogenes (age ≥2 months).

Approved (cream): Secondary infections of traumatic skin lesions due to S. aureus or S. pyogenes (age ≥3 months).

Off-label (ointment): Intranasal MRSA decolonization (previously covered by discontinued Bactroban nasal); perioperative Staph decolonization; catheter-exit site care in peritoneal dialysis patients.

Prescribing Guidance: Duration and Resistance Prevention

Key clinical prescribing principles for mupirocin in 2026:

Do not exceed 10 days of use; prolonged use promotes resistance and fungal overgrowth.

Reassess clinical response at 3–5 days; if no improvement, consider culture and alternative therapy.

Avoid use at IV catheter sites — associated with fungal infections and antimicrobial resistance promotion.

Caution in patients with moderate-to-severe renal impairment when using the PEG-based ointment on large wound areas.

Do not combine with other topical preparations at the same site — studies on concurrent application have not been performed.

Alternative Agents When Mupirocin Is Unavailable or Resistant

Retapamulin 1% ointment (Altabax): BID x5 days; MSSA and S. pyogenes only; not for MRSA; approved age ≥9 months. Dosing simplicity is a clinical advantage.

Ozenoxacin 1% cream (Xepi): BID x5 days; approved for age ≥2 months; broader spectrum; premium cost.

Oral cephalexin: Appropriate for extensive impetigo, bullous impetigo, or when topical therapy is impractical. Equally effective as topical mupirocin in clinical trials for MSSA.

Clindamycin or TMP-SMX (oral): For community-acquired MRSA skin infections; check local antibiogram for resistance rates.

Helping Patients Access Mupirocin

When patients struggle to find mupirocin in stock, medfinder for providers is a resource worth sharing. medfinder contacts pharmacies near the patient's location to identify which ones have the medication in stock, and texts results to the patient. This can save significant time for both patients and provider staff managing refill calls.

For patients on fixed incomes or without insurance, GoodRx and SingleCare coupons bring generic mupirocin ointment to as low as $4–$7 per 22g tube — making cost rarely a barrier for most patients.